Arpeggio Biosciences Raises $17 Million In Series A Funding Led By Builders Vc

Sep 07, 2022•over 3 years ago

Amount Raised

$17 Million

Round Type

series a

BoulderBiotechnology

Description

Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, and Builders VC, today announced a $17 million dollar Series A funding round, following a $3.2 million dollar seed round completed in 2020. Funding was led by Builders VC and will support ongoing development of Arpeggio’s drug pipeline as well as its transcription-monitoring technologies.

Company Information

Company

Arpeggio Bio

Location

4888 Pearl East Circle

Boulder, Colorado, United States

About

Arpeggio Biosciences is revolutionizing drug discovery by combining a proprietary biological assay with machine learning algorithms to generate rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots uncover the biological networks that drive a drug’s function, guiding more effective therapeutic development. Backed by a talented and diverse team, Arpeggio is dedicated to accelerating new treatments for patients with epigenetically-driven diseases.

Related People

3 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Arpeggio Biosciences Raises $17 Million In Series A Funding Led By Builders Vc

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information